Susquehanna International Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$553K Sell
39,802
-29,090
-42% -$409K ﹤0.01% 9395
2025
Q4
$832K Buy
+68,892
New +$936K ﹤0.01% 7589
2025
Q3
Sell
-110,846
Closed -$1.04M 12287
2025
Q2
$711K Sell
110,846
-1,360,079
-92% -$6.62M ﹤0.01% 8323
2025
Q1
$5.21M Buy
1,470,925
+602,543
+69% +$2.14M ﹤0.01% 3578
2024
Q4
$3.28M Buy
868,382
+462,225
+114% +$2.18M ﹤0.01% 4308
2024
Q3
$1.32M Sell
406,157
-39,881
-9% -$89.6K ﹤0.01% 6206
2024
Q2
$847K Buy
446,038
+199,239
+81% +$386K ﹤0.01% 6978
2024
Q1
$701K Sell
246,799
-316,141
-56% -$4.13M ﹤0.01% 7697
2023
Q4
$8.29M Buy
562,940
+346,186
+160% +$5.31M ﹤0.01% 2899
2023
Q3
$3.97M Buy
216,754
+193,751
+842% +$4.1M ﹤0.01% 3922
2023
Q2
$496K Sell
23,003
-7,607
-25% -$205K ﹤0.01% 8334
2023
Q1
$898K Buy
+30,610
New +$1.06M ﹤0.01% 7097
2022
Q4
Sell
-10,285
Closed -$365K 12313
2022
Q3
$290K Sell
10,285
-127,944
-93% -$3.19M ﹤0.01% 9874
2022
Q2
$2.66M Buy
138,229
+91,664
+197% +$1.09M ﹤0.01% 4300
2022
Q1
$598K Buy
+46,565
New +$1.05M ﹤0.01% 8502

Other funds holding AMLX

Susquehanna International Group's AMLX Position: Q1 2026 in Review

Susquehanna International Group reduced its Amylyx Pharmaceuticals (AMLX) stake by 42% in Q1 2026, selling an estimated $409K and leaving 39,802 shares worth $553K. The position accounts for ﹤0.01% of the portfolio, ranked #9395.

Susquehanna International Group first reported a position in AMLX in Q1 2022 and has held it in 15 quarters since. The position peaked at $8.29M in Q4 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Susquehanna International Group held 39,802 shares of Amylyx Pharmaceuticals worth $553K as of Q1 2026.
  • Susquehanna International Group sold 29,090 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $409K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9395 holding.
  • Susquehanna International Group first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 15 quarters since.
  • Susquehanna International Group's Amylyx Pharmaceuticals position peaked at $8.29M in Q4 2023.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.